Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  Kao, C ^a,b   Chao, A ^a   Tsai, C L ^a   Lin, C Y ^a   Chuang, W C ^a,b   Chen, H W ^a,b   Yen, T C ^c   Wang, T H ^a,b,c   Lai, C H ^a   Wang, H S ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bortezomib; Cisplatin; HSP70; JAK1; Ovarian cancer; STAT1

Indexed keywords

BORTEZOMIB; CISPLATIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; JANUS KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; JANUS KINASES; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; PHOSPHORYLATION; PYRAZINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875987607     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.38     Document Type: Article

References (54)

1. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
2. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008; 180: 6199-6210.
3. Pandit B, Gartel AL. Proteasome inhibitors suppress expression of NPM and ARF proteins. Cell Cycle 2011; 10: 3827-3829.
4. Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov 2003; 2: 611-612.
5. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-784.
6. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
7. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
8. Sironi JJ, Ouchi T. STAT1-induced apoptosis is mediated by caspases 2, 3, and 7. J Biol Chem 2004; 279: 4066-4074.
9. Vilcek J. Novel interferons. Nat Immunol 2003; 4: 8-9.
10. Chang CW, Tsai WH, Chuang WJ, Lin YS, Wu JJ, Liu CC et al. Procaspase 8 and Bax are up-regulated by distinct pathways in Streptococcal pyrogenic exotoxin B-induced apoptosis. J Biol Chem 2009; 284: 33195-33205.
11. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-9217.
12. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005; 92: 1149-1158.
13. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012CA Cancer J Clin 2012; 62: 10-29.
14. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
15. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin 2001; 51: 15-36.
16. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih IM et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006; 66: 3754-3763.
17. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005; 23: 5943-5949.
18. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6: 3719-3728.
19. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC et al. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2009; 115: 215-220.
20. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14: 250-262.
21. NCI Guidelines for Investigators: Adverse Event Reporting Requirements for DCTD(CTEP and CIP) and DCPINDs and IDE 2012 1-35.
22. ClinicalTrial.govhttp://clinicaltrials.gov/ct2/home 2012.
23. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
24. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556-7561.
25. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-820.
26. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997; 100: 3140-3148.
27. Zimmerman MA, Rahman NT, Yang D, Lahat G, Lazar AJ, Pollock RE et al. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res 2012; 72: 4724-4732.
28. Dimberg LY, Dimberg A, Ivarsson K, Fryknas M, Rickardson L, Tobin G et al. Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma. BMC Cancer 2012; 12: 318.
29. Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, Lovvorn HN et al. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis. Oncogene 2006; 25: 7555-7564.
30. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006; 281: 11923-11932.
31. Wolter KG, Verhaegen M, Fernandez Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007; 14: 1605-1616.
32. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M et al. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007; 12: 635-655.
33. Hsu WL, Chiu TH, Tai DJ, Ma YL, Lee EH. A novel defense mechanism that is activated on amyloid-beta insult to mediate cell survival: role of SGK1-STAT1/STAT2 signaling. Cell Death Differ 2009; 16: 1515-1529.
34. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478.
35. Stephanou A, Isenberg DA, Nakajima K, Latchman DS. Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem 1999; 274: 1723-1728.
36. Madamanchi NR, Li S, Patterson C, Runge MS. Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. J Biol Chem 2001; 276: 18915-18924.
37. Salvioli S, Storci G, Pinti M, Quaglino D, Moretti L, Merlo-Pich M et al. Apoptosis-resistant phenotype in HL-60-derived cells HCW-2 is related to changes in expression of stressinduced proteins that impact on redox status and mitochondrial metabolism. Cell Death Differ 2003; 10: 163-174.
38. Madamanchi NR, Li S, Patterson C, Runge MS. Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler Thromb Vasc Biol 2001; 21: 321-326.
39. Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011; 25: 1891-1899.
40. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 2010; 9: 2026-2036.
41. Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY et al. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Anticancer Drugs 2008; 19: 777-782.
42. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18: 449-455.
43. Al-Eisawi Z, Beale P, Chan C, Yu JQ, Huq F. Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration. Anticancer Res 2011; 31: 2757-2762.
44. Pasquini L, Petronelli A, Petrucci E, Saulle E, Mariani G, Scambia G et al. Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors. Int J Oncol 2010; 36: 707-713.
45. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006; 281: 31440-31447.
46. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011; 71: 4412-4422.
47. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009; 15: 553-560.
48. Guo HF, Su HL, Mao JJ, Sun C, Wang J, Zhou X. Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma. Int J Clin Pharmacol Ther 2010; 48: 776-778.
49. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T et al. Microtubuleinterfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998; 273: 4928-4936.
50. Lin CY, Liang YC, Yung BY. Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. Cell Signal 2006; 18: 2041-2048.
51. Yeh CW, Huang SS, Lee RP, Yung BY. Ras-dependent recruitment of c-Myc for transcriptional activation of nucleophosmin/B23 in highly malignant U1 bladder cancer cells. Mol Pharmacol 2006; 70: 1443-1453.
52. Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol 2004; 164: 1875-1882.
53. Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, Wang CJ et al. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett 2010; 291: 99-107.
54. Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 2006; 119: 91-98.